June 6REDWOOD CITY, California -- Synthego, the leading genome engineering solutions company, launches its Engineered Cells Portfolio with immediate access to Knockout Clone & Pool, and Advanced Cells. The Knockout Clone and Pool products enable single-click online ordering of any human cell line with a guaranteed CRISPR knockout. This guarantee combined with simplified access to CRISPR modified cells eliminates the hurdle of learning new methods and optimizing protocols, allowing scientists to focus on quality results. Advanced Cells allow researchers to leverage Synthego’s CRISPR expertise to design and execute complex cell modification projects.
CRISPR gives scientists the power of genome editing to tackle the biggest challenges presented in research, drug development and agriculture. Gaining the potential to make the edit you want is unprecedented, but the massive learning curve coupled with unpredictable results highlights the need to make CRISPR accessible to all.
"Gene editing technologies like CRISPR have dramatically improved how researchers make genomic modifications. As with many new biological tools, not everyone has the access, time, and ability to learn and use CRISPR efficiently to get the results they want. Due to these barriers, there is significant demand for products that make CRISPR accessible to the masses so researchers can focus on experimental outcomes rather than method development," said George Church, professor at Harvard & MIT. "Synthego is poised to meet that demand through the technology they have developed to automate CRISPR gene editing technology for engineering cells."
Furthermore, unpredictable results with utilizing CRISPR "do-it-yourself" methods like in vitro transcription and plasmid are slow and complicated. Leading scientists to look for products that have all the advantages of CRISPR without these downsides.
"Scientists want to use the best standard techniques in genome engineering, but it takes months to years to get cell line processes optimized in their lab," said Paul Dabrowski, CEO of Synthego. "With our experience running tens of thousands of genomic modifications supported by our platform built on deep bioinformatics modeling, and automation in a smart factory, we are productizing Engineered Cells. Every scientist now has easy access to the full power of CRISPR, without any learning curve. This launch marks a milestone for the genome engineering industry that will enable a new generation of researchers to focus on understanding biology and making cures, rather than learning and optimizing gene editing methods."
More About Synthego’s Engineered Cells Portfolio
Synthego’s Engineered Cells Portfolio includes:
"For important projects where it's critical we get the highest quality editing as quickly as possible, it makes the most sense to work with Synthego to have them engineer the cells for us," said Leif Oxburgh Senior Scientist, Maine Medical Center Research Institute."
To find out more about Synthego Engineered Cells visit www.synthego.com/products/engineered-cells/
Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies.
Greg Huegerich
VP, Marketing
[email protected]